Akeso (HKSE:09926) Additional Paid-In Capital : HK$6,078 Mil(As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Akeso Additional Paid-In Capital?

Akeso's quarterly additional paid-in capital increased from Jun. 2023 (HK$0 Mil) to Dec. 2023 (HK$5,015 Mil) and increased from Dec. 2023 (HK$5,015 Mil) to Jun. 2024 (HK$6,078 Mil).

Akeso's annual additional paid-in capital increased from Dec. 2021 (HK$4,907 Mil) to Dec. 2022 (HK$5,121 Mil) but then declined from Dec. 2022 (HK$5,121 Mil) to Dec. 2023 (HK$5,015 Mil).

Akeso Additional Paid-In Capital Historical Data

The historical data trend for Akeso's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akeso Additional Paid-In Capital Chart

Akeso Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

3,119.58

4,906.50

5,120.56

5,015.39

Akeso Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Additional Paid-In Capital	Get a 7-Day Free Trial							-	5,120.56	-	5,015.39	6,078.48

Akeso Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Akeso Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Akeso's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Akeso Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (HKSE:09926) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

AKESF:USA 4RY:Germany

Address

6 Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437

Website

https://www.akesobio.com

Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation, and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China.

Executives

Xia Yu	2501 Other
Wang Zhongmin Maxwell	2501 Other
Li Baiyong	2501 Other
Green Court Capital Holdings Limited	2201 Interest of corporation controlled by you
Green Court Capital Management Limited	2102 Investment manager
Green Court Management Holdings Llc	2201 Interest of corporation controlled by you
Yao Yulin	2201 Interest of corporation controlled by you
Shenzhen Capital Group Co., Ltd.	2201 Interest of corporation controlled by you
Xia Yu	2501 Other
Shen Zhen Shi Chuang Xin Tou Zi Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Zheng Xun
Zhong Shan Shi Xun Xiang Gu Quan Tou Zi Guan Li Qi Ye You Xian He Huo
Cantrust (far East) Limited	2301 Trustee
Aquae Hyperion Limited	2101 Beneficial owner
Htkf Investments Limited	2101 Beneficial owner

Akeso Headlines

No Headlines